Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.
Timothy J. Hobday
No relevant relationships to disclose
Rui Qin
No relevant relationships to disclose
Diane Lauren Reidy
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Jonathan R. Strosberg
No relevant relationships to disclose
Andreas Kaubisch
No relevant relationships to disclose
Manisha H. Shah
No relevant relationships to disclose
Hedy Lee Kindler
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech
Heinz-Josef Lenz
Consultant or Advisory Role - Roche/Genentech
Helen Chen
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose